Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...

Eli Lilly stock undercut its 50-day line on Jan. 14 after cutting its fourth-quarter and 2024 outlook. Is LLY stock a sell ...

But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...